Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 19, 2010 - Issue 10
Submit an article Journal homepage
222
Views
15
CrossRef citations to date
0
Altmetric
Original Research

No clinically relevant drug–drug interactions when dalcetrapib is co-administered with atorvastatin

Michael Derks F. Hoffmann-La Roche Ltd, Department of Clinical Pharmacology, Bldg. 663, Hochstrasse 16, CH-4070 Basel, Switzerland +41 61 68 79584; +41 61 68 86007; [email protected]
,
Markus Abt F. Hoffmann-La Roche Ltd, Statistics, Early Clinical Development, Basel, Switzerland
,
Graeme Parr Roche Products Ltd, Clinical Research and Exploratory Development-Study Management, Welwyn Garden City, UK
,
Georgina Meneses-Lorente Roche Products Ltd, Department of Clinical Pharmacology, Welwyn Garden City, UK
,
Anne-Marie Young Roche Products Ltd, Department of Clinical Pharmacology, Welwyn Garden City, UK
&
Mary Phelan Roche Products Ltd, Department of Clinical Pharmacology, Welwyn Garden City, UK
Pages 1135-1145 | Published online: 26 Aug 2010

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Amanda J Hooper & John R Burnett. (2012) Dalcetrapib, a cholesteryl ester transfer protein modulator. Expert Opinion on Investigational Drugs 21:9, pages 1427-1432.
Read now

Articles from other publishers (14)

Eric J Niesor, Guy Boivin, Eric Rhéaume, Rong Shi, Véronique Lavoie, Nathalie Goyette, Marie-Eve Picard, Anne Perez, Fouzia Laghrissi-Thode & Jean-Claude Tardif. (2021) Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib. ACS Omega 6:25, pages 16584-16591.
Crossref
Javier Reig-López, Alfredo García-Arieta, Víctor Mangas-Sanjuán & Matilde Merino-Sanjuán. (2021) Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making. Pharmaceutics 13:5, pages 709.
Crossref
Donald M. Black, Darren Bentley, Sunny Chapel, Jongtae Lee, Emily Briggs & Therese Heinonen. (2018) Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib. Clinical Pharmacokinetics 57:11, pages 1359-1367.
Crossref
Peng Duan, Ping Zhao & Lei Zhang. (2016) Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs). European Journal of Drug Metabolism and Pharmacokinetics 42:4, pages 689-705.
Crossref
Spencer Phillips HeyJessica M. FranklinJerry AvornAaron S. Kesselheim. (2017) Success, Failure, and Transparency in Biomarker-Based Drug Development. Circulation: Cardiovascular Quality and Outcomes 10:6.
Crossref
Tao Zhang. (2015) Physiologically based pharmacokinetic modeling of disposition and drug–drug interactions for atorvastatin and its metabolites. European Journal of Pharmaceutical Sciences 77, pages 216-229.
Crossref
Amir Hooshang Mohammadpour & Fatemeh Akhlaghi. (2013) Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective. Clinical Pharmacokinetics 52:8, pages 615-626.
Crossref
Mary Phelan, Judith Anzures-Cabrera, David J. Carlile, Lucy Rowell, Olaf Kuhlmann, Gerhard Arold, Richard Robson & Darren Bentley. (2013) Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dalcetrapib. Clinical Pharmacokinetics 52:4, pages 255-265.
Crossref
David RhaindsBenoit J ArsenaultMathieu R BrodeurJean-Claude Tardif. (2012) An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. Future Cardiology 8:4, pages 513-531.
Crossref
Tisha R. Joy. (2012) Novel HDL-based therapeutic agents. Pharmacology & Therapeutics 135:1, pages 18-30.
Crossref
Valerie Cheung & Robert A. Hegele. (2011) CETP Inhibitors: Will They Live up to Their Promise?. Current Cardiovascular Risk Reports 6:1, pages 4-11.
Crossref
Michael Derks, Hitoshi Kawamura, Markus Abt, Georgina Meneses-Lorente, Mary Phelan & Tomohiro Ishikawa. (2011) Effects of Food Intake on the Pharmacokinetic Properties of Dalcetrapib: Findings From Three Phase I, Single-Dose Crossover Studies in Healthy Volunteers. Clinical Therapeutics 33:6, pages 754-765.
Crossref
Michael Derks, Judith Anzures-Cabrera, Lynn Turnbull & Mary Phelan. (2012) Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects. Clinical Drug Investigation 31:5, pages 325-335.
Crossref
Michael Derks, Judith Anzures-Cabrera, Lynn Turnbull & Mary Phelan. (2011) Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects. Clinical Drug Investigation, pages 1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.